30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Fate Therapeutics Inc (FATE)

Track

Over the last 90 days, Fate Therapeutics Inc. has seen a net insider selling of approximately $102,566. This activity is primarily driven by executive sales, with no insider purchases recorded. The company's stock has experienced significant positive price movement in the past 90 days, rising by over 89%.
Stock chart
Ticker: FATE Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
TAHL CINDY
See Remarks
2 sales — total 96,167 USD
Sale 20 May 2026
Value US$2,014,150.47 | Price 23.67 | Shares 51,706
Proposed sale 20 May 2026
Value US$4,017,962.42 | Price 375.33 | Shares 27,478
Sale 20 May 2026
Value US$3,744,565.36 | Price 397.24 | Shares 67,971
Proposed sale 20 May 2026
Value US$2,891,031.26 | Price 376.87 | Shares 56,609
Sale 9 Jan 2026
Value US$11,275.17 | Price 1.06 | Shares 10,589
Proposed sale 9 Jan 2026
Value US$11,275.17 | Price 1.06 | Shares 10,589
Sale 9 Jan 2026
Value US$5,557.45 | Price 1.07 | Shares 5,190
Proposed sale 9 Jan 2026
Value US$5,557.45 | Price 1.07 | Shares 5,190
Proposed sale 24 Dec 2025
Value US$38,881.36 | Price 1.01 | Shares 38,428
Sale 4 Aug 2025
Value US$9,572.89 | Price 1.06 | Shares 9,037
Proposed sale 4 Aug 2025
Value US$9,572.89 | Price 1.06 | Shares 9,037
Sale 4 Aug 2025
Value US$15,396.16 | Price 1.06 | Shares 14,466
Proposed sale 4 Aug 2025
Value US$15,396.16 | Price 1.06 | Shares 14,466
Proposed sale 6 Mar 2025
Value US$104,881.48 | Price 0.93 | Shares 113,178
Sale 10 Jan 2025
Value US$9,269.00 | Price 1.55 | Shares 5,980
Proposed sale 10 Jan 2025
Value US$9,275.58 | Price 1.55 | Shares 5,980
Sale 10 Jan 2025
Value US$8,763.70 | Price 1.55 | Shares 5,654
Proposed sale 10 Jan 2025
Value US$8,782.36 | Price 1.55 | Shares 5,654
Sale 10 Jan 2025
Value US$13,405.70 | Price 1.54 | Shares 8,705
Proposed sale 10 Jan 2025
Value US$13,447.48 | Price 1.54 | Shares 8,705
Buy 20 Dec 2024
Value US$668,579.52 | Price 1.68 | Shares 397,964
Sale 20 Dec 2024
Value US$573,943.44 | Price 1.68 | Shares 341,633
Proposed sale 20 Dec 2024
Value US$567,110.78 | Price 1.66 | Shares 341,633
Planned sale 6 Aug 2024
Value US$2,677.59 | Price 4.23 | Shares 633
Proposed sale 6 Aug 2024
Value US$2,677.59 | Price 4.23 | Shares 633
Planned sale 4 Mar 2024
Value US$19,013.19 | Price 7.77 | Shares 2,447
Proposed sale 4 Mar 2024
Value US$19,013.19 | Price 7.77 | Shares 2,447
Planned sale 29 Jan 2024
Value US$9,245.00 | Price 5.00 | Shares 1,849
Proposed sale 29 Jan 2024
Value US$9,245.00 | Price 5.00 | Shares 1,849
Sale 9 Jan 2024
Value US$47,519.38 | Price 4.37 | Shares 10,874
Proposed sale 9 Jan 2024
Value US$47,471.54 | Price 4.37 | Shares 10,874
Sale 9 Jan 2024
Value US$49,366.98 | Price 4.38 | Shares 11,271
Proposed sale 9 Jan 2024
Value US$49,335.42 | Price 4.38 | Shares 11,271
Sale 9 Jan 2024
Value US$62,888.67 | Price 4.37 | Shares 14,391
Proposed sale 9 Jan 2024
Value US$62,957.75 | Price 4.37 | Shares 14,391
Sale 9 Jan 2024
Value US$30,712.36 | Price 4.37 | Shares 7,028
Proposed sale 9 Jan 2024
Value US$30,691.98 | Price 4.37 | Shares 7,028
Planned sale 2 Jan 2024
Value US$18,966.12 | Price 3.66 | Shares 5,182
Proposed sale 2 Jan 2024
Value US$18,966.12 | Price 3.66 | Shares 5,182
Buy 26 Dec 2023
Value US$166,023.60 | Price 3.72 | Shares 44,630
Planned sale 18 Dec 2023
Value US$5,547.50 | Price 3.50 | Shares 1,585
Proposed sale 18 Dec 2023
Value US$5,547.50 | Price 3.50 | Shares 1,585
Planned sale 9 Nov 2023
Value US$58,471.20 | Price 2.40 | Shares 24,363
Proposed sale 9 Nov 2023
Value US$58,471.20 | Price 2.40 | Shares 24,363
Sale 18 Aug 2023
Value US$13,210.40 | Price 2.80 | Shares 4,718
Proposed sale 18 Aug 2023
Value US$13,230.69 | Price 2.80 | Shares 4,718
Planned sale 4 Aug 2023
Value US$2,344.72 | Price 3.71 | Shares 632
Proposed sale 4 Aug 2023
Value US$2,344.72 | Price 3.71 | Shares 632
Planned sale 5 Jul 2023
Value US$25,029.06 | Price 4.83 | Shares 5,182
Proposed sale 5 Jul 2023
Value US$25,029.06 | Price 4.83 | Shares 5,182
Sale 5 Jul 2023
Value US$18,768.98 | Price 4.87 | Shares 3,854
Proposed sale 5 Jul 2023
Value US$18,758.19 | Price 4.87 | Shares 3,854
Planned sale 14 Jun 2023
Value US$19,306.80 | Price 5.58 | Shares 3,460
Proposed sale 14 Jun 2023
Value US$19,306.80 | Price 5.58 | Shares 3,460
Buy 21 Apr 2023
Value US$1,586,029.02 | Price 6.18 | Shares 256,639
Buy 20 Apr 2023
Value US$119,800.00 | Price 5.99 | Shares 20,000
Sale 18 Apr 2023
Value US$15,245.86 | Price 6.58 | Shares 2,317
Sale 18 Apr 2023
Value US$1,401.80 | Price 6.52 | Shares 215
Proposed sale 18 Apr 2023
Value US$16,653.72 | Price 6.58 | Shares 2,532
Buy 14 Apr 2023
Value US$154,200.00 | Price 6.00 | Shares 25,700
Sale 14 Apr 2023
Value US$1,765,659.76 | Price 5.84 | Shares 302,339
Proposed sale 14 Apr 2023
Value US$758,101.74 | Price 5.61 | Shares 135,134
Buy 13 Jan 2023
Value US$198,906.33 | Price 5.43 | Shares 36,631
Buy 11 Jan 2023
Value US$499,232.16 | Price 5.67 | Shares 88,048
Sale 10 Jan 2023
Value US$240,552.68 | Price 5.24 | Shares 45,907
Sale 10 Jan 2023
Value US$57,205.08 | Price 5.24 | Shares 10,917
Sale 10 Jan 2023
Value US$41,003.00 | Price 5.24 | Shares 7,825
Sale 10 Jan 2023
Value US$17,910.32 | Price 5.24 | Shares 3,418
Sale 10 Jan 2023
Value US$60,537.72 | Price 5.24 | Shares 11,553
Sale 10 Jan 2023
Value US$38,414.44 | Price 5.24 | Shares 7,331
Sale 18 Aug 2022
Value US$13,137.12 | Price 30.41 | Shares 432
Sale 18 Aug 2022
Value US$139,914.25 | Price 29.75 | Shares 4,703
Planned sale 22 Jul 2022
Value US$20,633.60 | Price 33.28 | Shares 620
Planned sale 22 Jul 2022
Value US$88,144.83 | Price 32.61 | Shares 2,703
Planned sale 22 Jul 2022
Value US$91,577.59 | Price 31.33 | Shares 2,923
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-21 2026-05-20 S Sale
4.0
TAHL CINDY

See Remarks

Officer
51,706 +19.0%
23.67
US$2,014,150 		51,706 +19.0% 23.67 US$2,014,150
2026-05-21 2026-05-20 S Sale
4.0
Valamehr Bahram

President and CEO

Executive Director
67,971 -34.1%
397.24
US$3,744,565 		67,971 -34.1% 397.24 US$3,744,565
2026-05-20 2026-05-20 PrS Proposed sale
4.0
Valamehr Bahram

Officer; Director

Executive Director
56,609
376.87
US$2,891,031 		56,609 376.87 US$2,891,031
2026-05-20 2026-05-20 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
25,590
1.88
US$48,084 		25,590 1.88 US$48,084
2026-01-12 2026-01-09 S Sale
4.0
TAHL CINDY

See Remarks

Officer
10,589 -2.7%
1.06
US$11,275 		10,589 -2.7% 1.06 US$11,275
2026-01-12 2026-01-09 S Sale
4.0
Valamehr Bahram

President and CEO

Executive Director
5,190 -1.5%
1.07
US$5,557 		5,190 -1.5% 1.07 US$5,557
2026-01-09 2026-01-09 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
10,589
1.06
US$11,275 		10,589 1.06 US$11,275
2026-01-09 2026-01-09 PrS Proposed sale
4.0
Valamehr Bahram

Officer; Director

Executive Director
5,190
1.07
US$5,557 		5,190 1.07 US$5,557
2025-12-29 2025-12-24 PrS Proposed sale
2.6
MENDLEIN JOHN

Former Director

Non-Executive Director
38,428
1.01
US$38,881 		38,428 1.01 US$38,881
2025-08-05 2025-08-04 S Sale
4.0
TAHL CINDY

See Remarks

Officer
9,037 -2.2%
1.06
US$9,573 		9,037 -2.2% 1.06 US$9,573
2025-08-05 2025-08-04 S Sale
4.0
Valamehr Bahram

President and CEO

Executive Director
14,466 -4.1%
1.06
US$15,396 		14,466 -4.1% 1.06 US$15,396
2025-08-04 2025-08-04 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
9,037
1.06
US$9,573 		9,037 1.06 US$9,573
2025-08-04 2025-08-04 PrS Proposed sale
4.0
Valamehr Bahram

Officer; Director

Executive Director
14,466
1.06
US$15,396 		14,466 1.06 US$15,396
2025-03-06 2025-03-06 PrS Proposed sale
4.0
Wolchko J Scott

Former Officer and Director

Executive Director
113,178
0.93
US$104,881 		113,178 0.93 US$104,881
2025-01-13 2025-01-10 S Sale
3.3
Bressi Jerome Charles

See Remarks

Officer
5,980 -2.2%
1.55
US$9,269 		5,980 -2.2% 1.55 US$9,269
2025-01-13 2025-01-10 S Sale
4.0
TAHL CINDY

See Remarks

Officer
5,654 -1.7%
1.55
US$8,764 		5,654 -1.7% 1.55 US$8,764
2025-01-13 2025-01-10 S Sale
4.0
Valamehr Bahram

President and CEO

Executive Director
8,705 -2.4%
1.54
US$13,406 		8,705 -2.4% 1.54 US$13,406
2025-01-10 2025-01-10 PrS Proposed sale
4.0
Valamehr Bahram

Officer; Director

Executive Director
8,705
1.54
US$13,447 		8,705 1.54 US$13,447
2025-01-10 2025-01-10 PrS Proposed sale
3.3
Bressi Jerome Charles

Officer

Officer
5,980
1.55
US$9,276 		5,980 1.55 US$9,276
2025-01-10 2025-01-10 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
5,654
1.55
US$8,782 		5,654 1.55 US$8,782
2024-12-26 2024-12-20 B Purchase
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
397,964 +3.2%
1.68
US$668,580 		397,964 +3.2% 1.68 US$668,580
2024-12-26 2024-12-20 S Sale
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
341,633 -2.7%
1.68
US$573,943 		341,633 -2.7% 1.68 US$573,943
2024-12-20 2024-12-20 PrS Proposed sale
3.2
Redmile Group, LLC

Director, 10% Stockholder

Non-Executive Director Large shareholder
341,633
1.66
US$567,111 		341,633 1.66 US$567,111
2024-08-07 2024-08-06 PlS Planned sale
Xu Yuan
Non-Executive Director
633 -6.8%
4.23
US$2,678 		633 -6.8% 4.23 US$2,678
2024-08-06 2024-08-06 PrS Proposed sale
Xu Yuan

Director

Non-Executive Director
633
4.23
US$2,678 		633 4.23 US$2,678
2024-03-05 2024-03-04 PlS Planned sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
2,447 -2.4%
7.77
US$19,013 		2,447 -2.4% 7.77 US$19,013
2024-03-04 2024-03-04 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
2,447
7.77
US$19,013 		2,447 7.77 US$19,013
2024-01-30 2024-01-29 PlS Planned sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
1,849 -1.7%
5.00
US$9,245 		1,849 -1.7% 5.00 US$9,245
2024-01-29 2024-01-29 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
1,849
5.00
US$9,245 		1,849 5.00 US$9,245
2024-01-10 2024-01-09 S Sale
4.0
TAHL CINDY

General Counsel and Secretary

Officer
10,874 -7.1%
4.37
US$47,519 		10,874 -7.1% 4.37 US$47,519
2024-01-10 2024-01-09 S Sale
4.0
Valamehr Bahram

Chief R&D Officer

Officer
11,271 -6.7%
4.38
US$49,367 		11,271 -6.7% 4.38 US$49,367
2024-01-10 2024-01-09 S Sale
4.0
Wolchko J Scott

President and CEO

Executive Director
14,391 -3.7%
4.37
US$62,889 		14,391 -3.7% 4.37 US$62,889
2024-01-10 2024-01-09 S Sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
7,028 -6.2%
4.37
US$30,712 		7,028 -6.2% 4.37 US$30,712
2024-01-09 2024-01-09 PrS Proposed sale
4.0
Wolchko J Scott

Officer; Director

Executive Director
14,391
4.37
US$62,958 		14,391 4.37 US$62,958
2024-01-09 2024-01-09 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
7,028
4.37
US$30,692 		7,028 4.37 US$30,692
2024-01-09 2024-01-09 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
10,874
4.37
US$47,472 		10,874 4.37 US$47,472
2024-01-09 2024-01-09 PrS Proposed sale
4.0
Valamehr Bahram

Officer

Officer
11,271
4.38
US$49,335 		11,271 4.38 US$49,335
2024-01-03 2024-01-02 PlS Planned sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
5,182 -4.4%
3.66
US$18,966 		5,182 -4.4% 3.66 US$18,966
2024-01-02 2024-01-02 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
5,182
3.66
US$18,966 		5,182 3.66 US$18,966
2023-12-28 2023-12-26 B Purchase
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
44,630 +0.3%
3.72
US$166,024 		44,630 +0.3% 3.72 US$166,024
2023-12-19 2023-12-18 PlS Planned sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
1,585 -1.3%
3.50
US$5,548 		1,585 -1.3% 3.50 US$5,548
2023-12-18 2023-12-18 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
1,585
3.50
US$5,548 		1,585 3.50 US$5,548
2023-11-13 2023-11-09 PlS Planned sale
4.0
TAHL CINDY

General Counsel and Secretary

Officer
24,363 -13.7%
2.40
US$58,471 		24,363 -13.7% 2.40 US$58,471
2023-11-09 2023-11-09 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
24,363
2.40
US$58,471 		24,363 2.40 US$58,471
2023-08-21 2023-08-18 S Sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
4,718 -3.8%
2.80
US$13,210 		4,718 -3.8% 2.80 US$13,210
2023-08-18 2023-08-18 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
4,718
2.80
US$13,231 		4,718 2.80 US$13,231
2023-08-07 2023-08-04 PlS Planned sale
Xu Yuan
Non-Executive Director
632 -6.4%
3.71
US$2,345 		632 -6.4% 3.71 US$2,345
2023-08-04 2023-08-04 PrS Proposed sale
Xu Yuan

Director

Non-Executive Director
632
3.71
US$2,345 		632 3.71 US$2,345
2023-07-06 2023-07-05 PlS Planned sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
5,182 -4.0%
4.83
US$25,029 		5,182 -4.0% 4.83 US$25,029
2023-07-06 2023-07-05 S Sale
3.2
Powl Brian T.

Chief Commercial Officer

Officer
3,854 -8.6%
4.87
US$18,769 		3,854 -8.6% 4.87 US$18,769
2023-07-05 2023-07-05 PrS Proposed sale
3.2
Powl Brian T.

Officer

Officer
3,854
4.87
US$18,758 		3,854 4.87 US$18,758
2023-07-05 2023-07-05 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
5,182
4.83
US$25,029 		5,182 4.83 US$25,029
2023-06-15 2023-06-14 PlS Planned sale
Xu Yuan
Non-Executive Director
3,460 -25.8%
5.58
US$19,307 		3,460 -25.8% 5.58 US$19,307
2023-06-14 2023-06-14 PrS Proposed sale
Xu Yuan

Director

Non-Executive Director
3,460
5.58
US$19,307 		3,460 5.58 US$19,307
2023-04-21 2023-04-21 B Purchase
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
256,639 +2.0%
6.18
US$1,586,029 		256,639 +2.0% 6.18 US$1,586,029
2023-04-21 2023-04-20 B Purchase
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
20,000 +0.2%
5.99
US$119,800 		20,000 +0.2% 5.99 US$119,800
2023-04-19 2023-04-18 S Sale
3.9
Chu Yu-Waye

Chief Medical Officer

Officer
2,317 -1.6%
6.58
US$15,246 		2,317 -1.6% 6.58 US$15,246
2023-04-19 2023-04-18 S Sale
3.9
Chu Yu-Waye

Chief Medical Officer

Officer
215 -0.2%
6.52
US$1,402 		215 -0.2% 6.52 US$1,402
2023-04-18 2023-04-18 PrS Proposed sale
3.9
Chu Yu-Waye

Officer

Officer
2,532
6.58
US$16,654 		2,532 6.58 US$16,654
2023-04-17 2023-04-14 B Purchase
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
25,700 +0.2%
6.00
US$154,200 		25,700 +0.2% 6.00 US$154,200
2023-04-17 2023-04-14 S Sale
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
302,339 -2.3%
5.84
US$1,765,660 		302,339 -2.3% 5.84 US$1,765,660
2023-04-14 2023-04-14 PrS Proposed sale
Redmile Capital Offshore Fund (ERISA), Ltd.

Director,10% Stockholder

Non-Executive Director Large shareholder
135,134
5.61
US$758,102 		135,134 5.61 US$758,102
2023-01-13 2023-01-13 B Purchase
2.6
MENDLEIN JOHN
Non-Executive Director
36,631 +14.9%
5.43
US$198,906 		36,631 +14.9% 5.43 US$198,906
2023-01-13 2023-01-11 B Purchase
2.6
MENDLEIN JOHN
Non-Executive Director
88,048 +55.7%
5.67
US$499,232 		88,048 +55.7% 5.67 US$499,232
2023-01-11 2023-01-10 S Sale
4.0
Wolchko J Scott

President and CEO

Executive Director
45,907 -10.6%
5.24
US$240,553 		45,907 -10.6% 5.24 US$240,553
2023-01-11 2023-01-10 S Sale
4.0
Valamehr Bahram

Chief R&D Officer

Officer
10,917 -6.1%
5.24
US$57,205 		10,917 -6.1% 5.24 US$57,205
2023-01-11 2023-01-10 S Sale
3.9
Chu Yu-Waye

Chief Medical Officer

Officer
7,825 -5.2%
5.24
US$41,003 		7,825 -5.2% 5.24 US$41,003
2023-01-11 2023-01-10 S Sale
3.1
Plavsic Mark

Chief Technical Officer

Officer
3,418 -2.7%
5.24
US$17,910 		3,418 -2.7% 5.24 US$17,910
2023-01-11 2023-01-10 S Sale
4.0
TAHL CINDY

General Counsel and Secretary

Officer
11,553 -6.1%
5.24
US$60,538 		11,553 -6.1% 5.24 US$60,538
2023-01-11 2023-01-10 S Sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
7,331 -5.4%
5.24
US$38,414 		7,331 -5.4% 5.24 US$38,414
2022-08-19 2022-08-18 S Sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
432 -0.3%
30.41
US$13,137 		432 -0.3% 30.41 US$13,137
2022-08-19 2022-08-18 S Sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
4,703 -3.3%
29.75
US$139,914 		4,703 -3.3% 29.75 US$139,914
2022-07-25 2022-07-22 PlS Planned sale
4.0
Wolchko J Scott

President and CEO

Executive Director
620 -0.1%
33.28
US$20,634 		620 -0.1% 33.28 US$20,634
2022-07-25 2022-07-22 PlS Planned sale
4.0
Wolchko J Scott

President and CEO

Executive Director
2,703 -0.6%
32.61
US$88,145 		2,703 -0.6% 32.61 US$88,145
2022-07-25 2022-07-22 PlS Planned sale
4.0
Wolchko J Scott

President and CEO

Executive Director
2,923 -0.7%
31.33
US$91,578 		2,923 -0.7% 31.33 US$91,578
Explore more

More insider trading research around Fate Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America